The estimated Net Worth of Philip J. Vickers is at least $352 millier dollars as of 7 July 2021. Philip Vickers owns over 4,800 units of AvroBio Inc stock worth over $6,720 and over the last 10 years he sold AVRO stock worth over $0. In addition, he makes $344,865 as Independent Director at AvroBio Inc.
Sign up
Philip Vickers AVRO stock SEC Form 4 insiders trading
Philip has made over 2 trades of the AvroBio Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 4,800 units of AVRO stock worth $40,080 on 7 July 2021.
The largest trade he's ever made was buying 4,800 units of AvroBio Inc stock on 7 July 2021 worth over $40,080. On average, Philip trades about 442 units every 67 days since 2015. As of 7 July 2021 he still owns at least 4,800 units of AvroBio Inc stock.
You can see the complete history of Philip Vickers stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Philip Vickers biography
Dr. Philip J. Vickers, Ph.D., serves as Director of the Company. Dr. Vickers is the president and chief executive officer and a member of the board of directors of Northern Biologics Inc., a biotechnology company, and has served in such roles since November 2017. From June 2013 until June 2017, Dr. Vickers served as global head of research and development and a member of the executive committee of Shire plc, a biotechnology company focused on the development of therapies for the treatment of rare and specialty conditions. From October 2010 to September 2013, Dr. Vickers served as the senior vice president, head of research and development, human genetic therapies at Shire. Prior to Shire, Dr. Vickers held positions of increasing responsibility in research and development at Merck & Co., Inc., Pfizer Inc., Boehringer-Ingelheim International GmbH and Resolvyx Pharmaceuticals, Inc. Dr. Vickers serves on the board of directors of Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company, and as a scientific advisor to the PTEN Research Foundation. Dr. Vickers obtained his Ph.D. in biochemistry from the University of Toronto, which was followed by postdoctoral research in mechanisms of multidrug resistance in breast cancer at the National Cancer Institute in Bethesda, Maryland.
What is the salary of Philip Vickers?
As the Independent Director of AvroBio Inc, the total compensation of Philip Vickers at AvroBio Inc is $344,865. There are 8 executives at AvroBio Inc getting paid more, with Birgitte Volck having the highest compensation of $4,384,270.
How old is Philip Vickers?
Philip Vickers is 60, he's been the Independent Director of AvroBio Inc since 2019. There are 4 older and 15 younger executives at AvroBio Inc. The oldest executive at AvroBio Inc is Christopher Paige, 67, who is the Independent Director.
What's Philip Vickers's mailing address?
Philip's mailing address filed with the SEC is C/O AVROBIO, INC., 100 TECHNOLOGY SQUARE, 6TH FLOOR, CAMBRIDGE, MA, 02139.
Insiders trading at AvroBio Inc
Over the last 6 years, insiders at AvroBio Inc have traded over $3,066,308 worth of AvroBio Inc stock and bought 2,395,057 units worth $31,037,133 . The most active insiders traders include Braden Michael Leonard, Bruce Booth et Venture Fund X, L.P.Atlas V.... On average, AvroBio Inc executives and independent directors trade stock every 102 days with the average trade being worth of $206,675. The most recent stock trade was executed by Braden Michael Leonard on 13 May 2024, trading 766,635 units of AVRO stock currently worth $973,626.
What does AvroBio Inc do?
clinical stage company focused on delivering step-change cell & gene therapies targeting cancer and rare disease.
What does AvroBio Inc's logo look like?
Complete history of Philip Vickers stock trades at Revance Therapeutics Inc et AvroBio Inc
AvroBio Inc executives and stock owners
AvroBio Inc executives and other stock owners filed with the SEC include:
-
Birgitte Volck,
President - Research & Development -
Erik Ostrowski,
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, Treasurer -
Geoff MacKay,
President, Chief Executive Officer, Director -
Steven Avruch,
Secretary, Chief Legal Officer -
Geoff MacKay BSc,
Co- Founder, Pres, CEO & Director -
Geoff MacKay,
Co- Founder, Pres, CEO & Director -
Erik Ostrowski M.B.A.,
CFO & Treasurer -
Steven N. Avruch J.D.,
Chief Legal Officer & Sec. -
Philip Vickers,
Independent Director -
Bruce Booth,
Independent Chairman of the Board -
Christopher Paige,
Independent Director -
Phillip Donenberg,
Independent Director -
Annalisa Jenkins,
Independent Director -
Ian Clark,
Independent Director -
Gail Farfel,
Director -
Kim Raineri,
Chief Manufacturing and Technology Officer -
Chris Brinzey,
IR Contact Officer -
Deanna Petersen,
Chief Business Officer -
Dr. Essra Ridha FFPM, M.D.,
Chief Medical Officer -
Andreas Kouri,
Sr. VP of Global Supply Chain & External Manufacturing -
Azadeh Golipour Ph.D.,
Chief Technology Officer -
Deanna M. Petersen MBA,
Chief Bus. Officer -
Dr. Christopher Mason FMEDSCI, FRCS, M.D., Ph.D.,
Chief Scientific Officer -
Dr. Christopher Mason FMEDSCI, M.D., Ph.D., FRCS,
Chief Scientific Officer -
Deanna M. Petersen M.B.A., MBA,
Chief Bus. Officer -
Georgette Verdin,
Chief HR Officer -
Monique Da Silva,
Sr. VP of Corp. Communications -
Dr. Christopher Mason,
Chief Scientific Officer -
Kim Raineri M.B.A.,
Chief Manufacturing & Technology Officer -
Matthew Arnold,
Head of Operations -
Jeffrey Medin Ph.D.,
Scientific Founder -
Venture Fund X, L.P.Atlas V...,
-
Lifesciences Iii, L.P.Claru...,
-
Scott Requadt,
Director -
Vi, Llcsv Life Sciences Fun...,
-
Katina Dorton,
Chief Financial Officer -
Nerissa Kreher,
Chief Medical Officer -
Venture Associates X, L.P. ...,
10% owner -
Lifesciences Iii, L.P.Claru...,
-
Diana Escolar,
Chief Medical Officer -
Christopher Mason,
Chief Scientific Officer -
Essra Ridha,
Chief Medical Officer -
Azadeh Golipour,
Chief Technology Officer -
Braden Michael Leonard,